Abstract
Thrombocytopenia in acute coronary syndromes (ACS) can arise from a variety of etiologies. Glycoprotein IIb/IIIa receptor antagonists have improved clinical outcomes in ACS, however, profound thrombocytopenia can occur with use of these agents. We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction. We review the major causes and suggest an approach for diagnosis and management of thrombocytopenia in ACS.
Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Acute Coronary Syndrome / diagnosis
-
Acute Coronary Syndrome / therapy
-
Angioplasty, Balloon, Coronary / methods*
-
Aspirin / therapeutic use
-
Clopidogrel
-
Drug Therapy, Combination
-
Electrocardiography / methods
-
Enzyme-Linked Immunosorbent Assay
-
Eptifibatide
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Myocardial Infarction / diagnosis
-
Myocardial Infarction / therapy*
-
Peptides / adverse effects*
-
Peptides / therapeutic use
-
Platelet Aggregation Inhibitors / adverse effects*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Platelet Count
-
Platelet Transfusion
-
Risk Assessment
-
Thrombocytopenia / chemically induced*
-
Thrombocytopenia / physiopathology
-
Thrombocytopenia / therapy*
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Treatment Outcome
Substances
-
Peptides
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Eptifibatide
-
Ticlopidine
-
Aspirin